Corcept Therapeutics Incorporated's (NASDAQ:CORT) P/E Is Still On The Mark Following 37% Share Price Bounce

Simply Wall StFeb 13 06:42 ET

Insider Sale: Director at $CORT Sells 2,200 Shares

Quiver QuantitativeFeb 12 20:30 ET

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

BusinesswireFeb 12 16:05 ET

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $115

BenzingaFeb 11 06:50 ET · Ratings

Citi Initiates Corcept Therapeutics(CORT.US) With Buy Rating, Announces Target Price $115

Moomoo NewsFeb 11 06:33 ET · Ratings

H.C. Wainwright Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Raises Target Price to $115

Moomoo NewsFeb 11 06:33 ET · Ratings